Suven Life Sciences says positive topline results from a Phase-2 study evaluating samelisant excessive daytime sleepiness Posted by Able on October 30, 2023 Get link Facebook X Pinterest Email Other Apps Plans to approach USFDA in Q1 2024 for an end-of- phase-2 meeting to discuss study resultsPlans to seek USFDA's guidance for pivotal phase-3 study Comments
Comments
Post a Comment